Login to Your Account

Phase II testing in lymphoma up next
LONDON - The T-cell cancer immunotherapy bandwagon keeps rolling on, with Cell Medica Ltd. announcing the close of a remarkable £50 million (US$78 million) series B to fund development of its autologous treatment for Epstein-Barr virus (EBV)-related lymphomas. more »


Partners in Focus